Dublin, Aug. 23, 2023 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder (ASD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering.
This reports provides a data-driven overview of the current and future competitive landscape in ASD therapeutics.
There will be over 9.8 million diagnosed prevalent cases of ASD in 2023 in the 16 countries covered in the epidemiology forecast. The current ASD market is highly genericized, with only two products approved by the FDA.
The ASD pipeline consists of 127 drugs spanning all stages of development, with only 7% of drugs present in Phase III. Of the 432 trials initiated in ASD in the past 10 years, 247 trials have been completed.
Partnerships were the most common deal type executed globally in the ASD space.
The report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the ASD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ASD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
List of Report Chapters
1 Preface
2 Key Findings
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
8 Deals Landscape
9 Commercial Assessment
10 Future Market Catalysts
11 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/sls3d4
Source: GlobalData
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
